The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Open accessAbstract
Background —Elevated plasma concentrations of C-reactive protein (CRP) are associated with increased cardiovascular risk. We evaluated whether long-term therapy with pravastatin, an agent that reduces cardiovascular risk, might alter levels of this inflammatory parameter. Methods and Results —CRP levels were measured at baseline and at 5 years in 472 randomly selected participants in the Cholesterol and Recurrent Events (CARE) trial who remained free of recurrent coronary events during follow-up. Overall, CRP levels at baseline and at 5 years were highly correlated ( r =0.60, P <0.001). However, among those allocated to placebo, median CRP levels and the mean change in CRP tended to increase over time (median change, +4.2%; P =0.2 and mean change, +0.07 mg/dL; P =0.04). By contrast, median CRP levels and the mean change in CRP decreased over time among those allocated to pravastatin (median change, −17.4%; P =0.004 and mean change, −0.07 mg/dL; P =0.002). Thus, statistically significant differences were observed at 5 years between the pravastatin and placebo groups in terms of median CRP levels (difference, −21.6%; P =0.007), mean CRP levels (difference, −37.8%; P =0.002), and absolute mean change in CRP (difference, −0.137 mg/dL; P =0.003). These effects persisted in analyses stratified by age, body mass index, smoking status, blood pressure, and baseline lipid levels. Attempts to relate the magnitude of change in CRP to the magnitude of change in lipids in both the pravastatin and placebo groups did not reveal any obvious relationships. Conclusions —Among survivors of myocardial infarction on standard therapy plus placebo, CRP levels tended to increase over 5 years of follow-up. In contrast, randomization to pravastatin resulted in significant reductions in this inflammatory marker that were not related to the magnitude of lipid alterations observed. Thus, these data further support the potential for nonlipid effects of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,357
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.98.8.731 · Cited by 1,642
Self-citationProduction of C-reactive protein and risk of coronary events in stable and unstable angina
Haverkate, E., Thompson, S. G., Pyke, S. D., Gallimore, J. R., & Group, M. B. P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07591-5 · Cited by 1,500
Cited by
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Self-citationBiomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationRidker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citationC-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Role of C-Reactive Protein at Sites of Inflammation and Infection
Sproston, N. R., & Ashworth, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00754 · Cited by 3,029
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Self-citationSchwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citationPLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.102.18.2165 · Cited by 1,940
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,641
Self-citationRidker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citationCurrent Concepts of the Pathogenesis of the Acute Coronary Syndromes
Libby, P. (2001) · Circulation · doi:10.1161/01.cir.104.3.365 · Cited by 1,558
Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes
Pickup, J. C. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.813 · Cited by 1,414
Ridker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
Self-citationChung, M. K., Martin, D. O., Sprecher, D., Wazni, O., Kanderian, A., Carnes, C. A., Bauer, J. A., Tchou, P. J., Niebauer, M. J., Natale, A., et al. (2001) · Circulation · doi:10.1161/hc4901.101760 · Cited by 1,375
Inflammation as a Cardiovascular Risk Factor
Willerson, J. T., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000129535.04194.38 · Cited by 1,304
Self-citationPleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,272
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk
Meier-Ewert, H. K., Ridker, P. M., Rifai, N., Regan, M. M., Price, N. J., Dinges, D. F., & Mullington, J. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.050 · Cited by 1,195
“Although IL-6 levels display circadian variability, CRP levels have been shown to be quite stable across 24 h (15) and, in the absence of disease, are quite reproducible, even over weeks and months ( 16 ).”
BackgroundMethodInfluentialSelf-citationObstructive Sleep Apnea: Implications for Cardiac and Vascular Disease
Shamsuzzaman, A. S. M., Gersh, B. J., & Somers, V. K. (2003) · JAMA · doi:10.1001/jama.290.14.1906 · Cited by 1,188
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Self-citationCrisby, M., Nordin-Fredriksson, G., Shah, P. K., Yano, J., Zhu, J., & Nilsson, J. (2001) · Circulation · doi:10.1161/01.cir.103.7.926 · Cited by 1,001
Elevated C-Reactive Protein in Patients With Obstructive Sleep Apnea
Shamsuzzaman, A. S. M., Winnicki, M., Lanfranchi, P., Wolk, R., Kara, T., Accurso, V., & Somers, V. K. (2002) · Circulation · doi:10.1161/01.cir.0000018948.95175.03 · Cited by 974
Beneficial Cardiovascular Pleiotropic Effects of Statins
Davignon, J. (2004) · Circulation · doi:10.1161/01.cir.0000131517.20177.5a · Cited by 955
Stenvinkel, P., Ketteler, M., Johnson, R. J., Lindholm, B., Pecoits-Filho, R., Riella, M., Heimbürger, O., Cederholm, T., & Girndt, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00200.x · Cited by 932
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Packard, R. R. S., & Libby, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097360 · Cited by 925
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915
Self-citationChanges in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 914
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 905
Research Progress on the Relationship between Atherosclerosis and Inflammation
Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., Tang, D., & Chen, R. (2018) · Biomolecules · doi:10.3390/biom8030080 · Cited by 872
Pasceri, V., Chang, J., Willerson, J. T., & Yeh, E. T. H. (2001) · Circulation · doi:10.1161/01.cir.103.21.2531 · Cited by 831
Oberg, B. P., McMenamin, E., Lucas, F. L., McMonagle, E., Morrow, J., Ikizler, T. A. L. P., & Himmelfarb, J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00465.x · Cited by 781
Novel Clinical Markers of Vascular Wall Inflammation
Blake, G. J., & Ridker, P. M. (2001) · Circulation Research · doi:10.1161/hh2101.099270 · Cited by 754
Self-citationJialal, I., Stein, D., Balis, D., Grundy, S. M., Adams-Huet, B., & Devaraj, S. (2001) · Circulation · doi:10.1161/01.cir.103.15.1933 · Cited by 730
Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study
Schmidt, R., Schmidt, H., Curb, J. D., Masaki, K., White, L. R., & Launer, L. J. (2002) · Annals of Neurology · doi:10.1002/ana.10265 · Cited by 710
Inflammatory bio‐markers and cardiovascular risk prediction
Blake, G. J., & Ridker, P. M. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01019.x · Cited by 702
Self-citationTargeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Pradhan, A. D., Manson, J. E., Rossouw, J. E., Siscovick, D. S., Mouton, C. P., Rifai, N., Wallace, R. B., Jackson, R. D., Pettinger, M. B., & Ridker, P. M. (2002) · JAMA · doi:10.1001/jama.288.8.980 · Cited by 680
Self-citationSimvastatin Attenuates Plaque Inflammation
Tahara, N., Kai, H., Ishibashi, M., Nakaura, H., Kaida, H., Baba, K., Hayabuchi, N., & Imaizumi, T. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.069 · Cited by 654
Ridker, P. M., Wilson, P. W. F., & Grundy, S. M. (2004) · Circulation · doi:10.1161/01.cir.0000132467.45278.59 · Cited by 645
Self-citationC-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
Ridker, P. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.052 · Cited by 623
Self-citationMevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
NACB WRITING GROUP MEMBERS, Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H. B., & Christenson, R. H. (2007) · Circulation · doi:10.1161/circulationaha.107.182882 · Cited by 610
Liu, S., Manson, J. E., Buring, J. E., Stampfer, M. J., Willett, W. C., & Ridker, P. M. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.3.492 · Cited by 594
Self-citationElevated C-Reactive Protein: Another Component of the Atherothrombotic Profile of Abdominal Obesity
Lemieux, I., Pascot, A., Prud’homme, D., Alméras, N., Bogaty, P., Nadeau, A., Bergeron, J., & Després, J.-P. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.6.961 · Cited by 590
Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target
Golia, E., Limongelli, G., Natale, F., Fimiani, F., Maddaloni, V., Pariggiano, I., Bianchi, R., Crisci, M., D’Acierno, L., Giordano, R., et al. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0435-z · Cited by 560
Taylor, A. J., Kent, S. M., Flaherty, P. J., Coyle, L. C., Markwood, T. T., & Vernalis, M. N. (2002) · Circulation · doi:10.1161/01.cir.0000034508.55617.65 · Cited by 558
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Is atrial fibrillation an inflammatory disorder?
Boos, C. J., Anderson, R. A., & Lip, G. Y. H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi645 · Cited by 552
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Self-citationEarly Statin Treatment Following Acute Myocardial Infarction and 1-Year Survival
Stenestrand, U. (2001) · JAMA · doi:10.1001/jama.285.4.430 · Cited by 530
Statin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 527
High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease
Rifai, N., & Ridker, P. M. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.3.403 · Cited by 521
Self-citationInflammation and Infections as Risk Factors for Ischemic Stroke
Lindsberg, P. J., & Grau, A. J. (2003) · Stroke · doi:10.1161/01.str.0000089015.51603.cc · Cited by 519
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
Serum Inflammatory Markers in Obstructive Sleep Apnea: A Meta-Analysis
Nadeem, R., Molnar, J., Madbouly, E. M., Nida, M., Aggarwal, S., Sajid, H., Naseem, J., & Loomba, R. (2013) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.3070 · Cited by 481
Il'yasova, D., Colbert, L. H., Harris, T. B., Newman, A. B., Bauer, D. C., Satterfield, S., & Kritchevsky, S. B. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0316 · Cited by 479
Transcription factor-κB (NF-κB) and renal disease
Guijarro, C., & Egido, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002415.x · Cited by 479
NACB WRITING GROUP MEMBERS, Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H. B., Christenson, R. H., NACB COMMITTEE MEMBERS, et al. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.084194 · Cited by 474
Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy
Shishehbor, M. H., Aviles, R. J., Brennan, M.-L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Penn, M. S., Sprecher, D. L., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1675 · Cited by 464
Lesko, L., & Atkinson, A. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.347 · Cited by 465
High-sensitivity C-reactive proteinClinical importance
BASSUK, S., RIFAI, N., & RIDKER, P. (2004) · Current Problems in Cardiology · doi:10.1016/s0146-2806(04)00074-x · Cited by 464
Self-citationTargeting cardiovascular inflammation: next steps in clinical translation
Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa099 · Cited by 443
Self-citationChambers, J. C., Eda, S., Bassett, P., Karim, Y., Thompson, S. G., Gallimore, J. R., Pepys, M. B., & Kooner, J. S. (2001) · Circulation · doi:10.1161/01.cir.104.2.145 · Cited by 438
Kopp, H. P., Kopp, C. W., Festa, A., Krzyzanowska, K., Kriwanek, S., Minar, E., Roka, R., & Schernthaner, G. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000073313.16135.21 · Cited by 427
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
Williams, D., & Feely, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00003 · Cited by 423
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 421
Self-citationEndothelium-Dependent Effects of Statins
Wolfrum, S., Jensen, K. S., & Liao, J. K. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000063385.12476.a7 · Cited by 417
Ridker, P. M., Rifai, N., & Lowenthal, S. P. (2001) · Circulation · doi:10.1161/01.cir.103.9.1191 · Cited by 415
Self-citationShetty, G. K., Economides, P. A., Horton, E. S., Mantzoros, C. S., & Veves, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2450 · Cited by 415
Heeschen, C., Hamm, C. W., Bruemmer, J., & Simoons, M. L. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00581-7 · Cited by 414
Ockene, I. S., Matthews, C. E., Rifai, N., Ridker, P. M., Reed, G., & Stanek, E. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.3.444 · Cited by 411
Self-citationAbsence of diurnal variation of C-reactive protein concentrations in healthy human subjects
Meier-Ewert, H. K., Ridker, P. M., Rifai, N., Price, N., Dinges, D. F., & Mullington, J. M. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.3.426 · Cited by 410
Self-citationSoppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways
Shishehbor, M. H., Brennan, M.-L., Aviles, R. J., Fu, X., Penn, M. S., Sprecher, D. L., & Hazen, S. L. (2003) · Circulation · doi:10.1161/01.cir.0000080895.05158.8b · Cited by 405
Fliser, D., Buchholz, K., & Haller, H. (2004) · Circulation · doi:10.1161/01.cir.0000140265.21608.8e · Cited by 404
Coming of Age of C-Reactive Protein: Using Inflammation Markers in Cardiology
Yeh, E. T. H., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000053731.05365.5a · Cited by 403
Kuo, H.-K., Yen, C.-J., Chang, C.-H., Kuo, C.-K., Chen, J.-H., & Sorond, F. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70099-5 · Cited by 399
Arici, M., & Walls, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002407.x · Cited by 398
Jorge, M. L. M. P., de Oliveira, V. N., Resende, N. M., Paraiso, L. F., Calixto, A., Diniz, A. L. D., Resende, E. S., Ropelle, E. R., Carvalheira, J. B., Espindola, F. S., et al. (2011) · Metabolism · doi:10.1016/j.metabol.2011.01.006 · Cited by 398
Myers, G. L., Rifai, N., Tracy, R. P., Roberts, W. L., Alexander, R. W., Biasucci, L. M., Catravas, J. D., Cole, T. G., Cooper, G. R., Khan, B. V., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148980.87579.5e · Cited by 391
Self-citationGoldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 373
Circulating markers of inflammation and atherosclerosis
Lind, L. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00012-1 · Cited by 369
C-reactive protein and other inflammatory risk markers in acute coronary syndromes
Blake, G. J., & Ridker, P. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02953-4 · Cited by 367
Self-citationC‐reactive protein and coronary heart disease: a critical review
Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., & Pepys, M. B. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02015.x · Cited by 366
Plenge, J. K., Hernandez, T. L., Weil, K. M., Poirier, P., Grunwald, G. K., Marcovina, S. M., & Eckel, R. H. (2002) · Circulation · doi:10.1161/01.cir.0000029743.68247.31 · Cited by 354
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Self-citationStatin therapy is associated with improved survival in ischemic and non-ischemic heart failure
Horwich, T. B., MacLellan, W. R., & Fonarow, G. C. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.049 · Cited by 341
C-reactive protein and the biology of disease
Ansar, W., & Ghosh, S. (2013) · Immunologic Research · doi:10.1007/s12026-013-8384-0 · Cited by 336
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 336
Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.066 · Cited by 335
Self-citationHeilbronn, L. K., Noakes, M., & Clifton, P. M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.6.968 · Cited by 331
Bellamy, M. F., Pellikka, P. A., Klarich, K. W., Tajik, A. J., & Enriquez-Sarano, M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02496-8 · Cited by 321
Timpson, N. J., Nordestgaard, B. G., Harbord, R. M., Zacho, J., Frayling, T. M., Tybjærg-Hansen, A., & Davey Smith, G. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.137 · Cited by 310
Calabro, P., Chang, D. W., Willerson, J. T., & Yeh, E. T. H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.017 · Cited by 308
Metadata
- Authors
- Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E.
- Venue
- Circulation
- Published
- 1999-07-20
- Volume
- 100
- Issue
- 3
- Pages
- 230-235
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2145053304
- Cited by
- 1,478
- References
- 25
- FWCI
- 114.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.